PubMed · 2796839
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D Uhl. 1989. [Headlines].. https://pubmed.ncbi.nlm.nih.gov/2796839/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
More women than men eventually develop hypertension, but they suffer less cardiovascular damage as a consequence. Primary hypertension in women has a greater volume component, often related to commonly associated obesity. Most lifestyle modifications have more to offer women, but women respond in a similar manner to various antihypertensive drugs. However, women appear to receive less benefit from antihypertensive therapy, as measured by morbidity and mortality data in multiple large clinical trials. Women who take oral contraceptives typically have a small rise in blood pressure, and in a small percentage, the rise is sufficient to induce hypertension. The prevalence is likely lower with currently used low-dose estrogen formulations. The use of estrogen for postmenopausal replacement therapy almost never raises the blood pressure, so that concerns about hypertension should not interfere with the use of this valuable therapy.
The opinions of 20 international experts in reproductive endocrinology and family planning service delivery were solicited concerning contraceptive pill use during breastfeeding and, in particular, to determine whether the experts felt that breastfeeding women who use progestin-only pills (POPs) should be advised to switch to combined estrogen-progestin pills (COCs) during lactation. The experts agreed that POPs can be used safely and effectively throughout the period of lactation and there is no need to switch to another contraceptive method or another type of pill. If, however, a woman wishes to switch to COCs while she is still breastfeeding, it is acceptable for her to do so after six months postpartum.
Numerous literature references have suggested increased risk for localized alveolar osteitis associated with female gender, use of oral contraceptives, and point in menstrual/contraceptive cycle. However, the available information has not been systematically considered with the intent to accurately estimate the magnitude of these effects. The present review suggests that under certain conditions, some of which may be avoidable, females may have at least a two to threefold increase in osteitis risk compared with males. It appears that this greater risk may be reduced by considering hormonal cycles when scheduling elective exodontia.